Medicare Bridge Model Enrolled 1.1 Million Beneficiaries
The pilot program offers eligible members $50 monthly access to GLP-1 medications for weight-related care.
Updated on Oct. 14, 2026 in Diabetes
Live Poll
Should the federal government expand discounted drug access programs for Medicare beneficiaries?
The Centers for Medicare and Medicaid Services (CMS) has enrolled 1.1 million beneficiaries in its Bridge model pilot, which provides significant cost relief for GLP-1 medications. This program aims to support Medicare Part D members who need these treatments for obesity management rather than Type 2 diabetes.
Why it matters
The program addresses a major access barrier by capping the monthly cost of these prescriptions at $50 for eligible participants. This initiative helps manage out-of-pocket expenses while CMS evaluates the utilization of these medications within the Medicare population.
Official figures confirm 1.1 million beneficiaries have enrolled in the Bridge model since the launch, with CVS Health and Walgreens each reporting over 100,000 prescriptions dispensed. The full clinical impact of this widespread utilization is not yet known.
The players
CMS
The federal agency that administers the Medicare program and oversees insurance coverage for millions of Americans.
CVS Health
A major pharmacy retail chain and healthcare provider involved in dispensing GLP-1 medications through Medicare programs.
Walgreens
A national pharmacy retail chain currently participating in the dispensing of GLP-1 medications for Medicare beneficiaries.
HHS
The federal department responsible for protecting the health of all Americans and providing essential human services.
The details
The Bridge model allows Medicare Part D beneficiaries to access GLP-1 medications at a reduced cost of $50 per month, compared to standard market prices. By facilitating access for patients seeking obesity treatment outside of a Type 2 diabetes diagnosis, CMS is gathering data on how these therapies function within the federal healthcare system. Starting in the fall, CMS will share monthly utilization reports with Part D plans to monitor the program’s trajectory.
Timeline
July 1, 2026: The Bridge model pilot officially launched.
August 2026: CMS announced plans for ongoing monthly utilization reporting.
Late August and early September 2026: Pharmacies reported dispensing 100,000 prescriptions each.
October 7, 2026: An HHS official disclosed the latest enrollment figures.
End of 2027: The pilot program is currently scheduled to conclude.
Health Landscape
The Bridge model marks a strategic shift following the delay of the BALANCE pilot, representing the agency's current approach to expanding access to weight-loss therapies. This initiative underscores the evolving role of GLP-1 treatments in public health policy.
If you are a Medicare Part D beneficiary, consider discussing your eligibility for the Bridge model with your physician to see if it applies to your current treatment plan. Keep in mind that this program is specifically designed for beneficiaries needing anti-obesity medications for non-diabetic conditions.
The takeaway
The CMS Bridge model offers a critical pathway to lower-cost GLP-1 medications for eligible Medicare beneficiaries. Patients should consult their pharmacist or doctor to determine if they qualify for this program and how it might impact their ongoing care for weight management.
What happens next
CMS will begin providing monthly utilization reports to Part D plans starting in the fall of 2026 to track the program's progress.
Further reading
Learn more about the latest Diabetes management policies and coverage updates.
Source note: This article includes information reported by Becker's Hospital Review | Healthcare News & Analysis.
Live Poll
Should the federal government expand discounted drug access programs for Medicare beneficiaries?
